IDEAYA Biosciences (IDYA) Competitors $15.28 -1.07 (-6.54%) As of 12:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDYA vs. AXSM, TLX, BPMC, KRYS, NUVL, CYTK, VRNA, GRFS, ELAN, and ADMAShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Krystal Biotech (KRYS), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), Grifols (GRFS), Elanco Animal Health (ELAN), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. IDEAYA Biosciences vs. Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Krystal Biotech Nuvalent Cytokinetics Verona Pharma Grifols Elanco Animal Health ADMA Biologics IDEAYA Biosciences (NASDAQ:IDYA) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Do institutionals and insiders believe in IDYA or AXSM? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 3.5% of IDEAYA Biosciences shares are held by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to IDYA or AXSM? In the previous week, Axsome Therapeutics had 14 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 25 mentions for Axsome Therapeutics and 11 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.65 beat Axsome Therapeutics' score of 0.38 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Axsome Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Which has more volatility & risk, IDYA or AXSM? IDEAYA Biosciences has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Does the MarketBeat Community prefer IDYA or AXSM? Axsome Therapeutics received 335 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. However, 71.72% of users gave IDEAYA Biosciences an outperform vote while only 70.46% of users gave Axsome Therapeutics an outperform vote. CompanyUnderperformOutperformIDEAYA BiosciencesOutperform Votes14271.72% Underperform Votes5628.28% Axsome TherapeuticsOutperform Votes47770.46% Underperform Votes20029.54% Which has stronger valuation & earnings, IDYA or AXSM? IDEAYA Biosciences has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M204.46-$274.48M-$3.30-4.95Axsome Therapeutics$385.69M13.88-$287.22M-$5.99-18.32 Do analysts recommend IDYA or AXSM? IDEAYA Biosciences currently has a consensus price target of $53.58, indicating a potential upside of 227.73%. Axsome Therapeutics has a consensus price target of $167.64, indicating a potential upside of 52.75%. Given IDEAYA Biosciences' higher probable upside, equities analysts clearly believe IDEAYA Biosciences is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.93Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IDYA or AXSM more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -74.47%. IDEAYA Biosciences' return on equity of -26.74% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -26.74% -25.54% Axsome Therapeutics -74.47%-223.51%-39.88% SummaryIDEAYA Biosciences beats Axsome Therapeutics on 12 of the 19 factors compared between the two stocks. Remove Ads Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-4.957.1123.0918.81Price / Sales204.46207.46368.8188.91Price / CashN/A65.6738.1634.64Price / Book1.356.146.694.18Net Income-$274.48M$142.11M$3.20B$247.10M7 Day Performance-6.20%-6.00%-3.93%-2.72%1 Month Performance-14.53%-6.96%1.69%-3.90%1 Year Performance-61.21%-12.14%8.39%-0.11% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences3.3033 of 5 stars$15.28-6.5%$53.58+250.7%-60.6%$1.34B$7M-4.6380News CoveragePositive NewsAXSMAxsome Therapeutics4.6912 of 5 stars$129.17+1.9%$167.36+29.6%+47.2%$6.30B$385.69M-21.56380Analyst ForecastShort Interest ↓News CoverageGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.38+3.3%$22.00+19.7%N/A$6.19B$783.21M0.00N/AGap UpBPMCBlueprint Medicines2.7875 of 5 stars$95.27+7.4%$124.95+31.2%-1.7%$6.09B$508.82M-88.21640News CoveragePositive NewsGap DownKRYSKrystal Biotech4.8274 of 5 stars$194.44+3.9%$220.00+13.1%+2.3%$5.60B$290.52M65.03210Positive NewsGap DownNUVLNuvalent2.4194 of 5 stars$77.14-1.1%$113.10+46.6%-4.0%$5.52BN/A-22.2340Positive NewsGap DownCYTKCytokinetics4.0716 of 5 stars$46.57+2.5%$82.00+76.1%-43.3%$5.51B$18.47M-8.66250Insider TradeAnalyst RevisionNews CoverageGap DownVRNAVerona Pharma2.538 of 5 stars$66.780.0%$69.14+3.5%+278.5%$5.40B$42.28M-34.7830Gap DownGRFSGrifols4.0338 of 5 stars$7.75-0.5%N/A+10.5%$5.33B$7.21B6.6226,300News CoverageELANElanco Animal Health4.039 of 5 stars$10.69+1.6%$15.17+41.8%-30.7%$5.29B$4.44B26.749,800Gap DownADMAADMA Biologics2.4229 of 5 stars$20.32+2.6%$22.50+10.7%+214.1%$4.80B$426.45M72.57530Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Axsome Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Blueprint Medicines Alternatives Krystal Biotech Alternatives Nuvalent Alternatives Cytokinetics Alternatives Verona Pharma Alternatives Grifols Alternatives Elanco Animal Health Alternatives ADMA Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDYA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
